| 1 |
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
|
| 2 |
American Cancer Society. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007: 12-13.
|
| 3 |
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249.
|
| 4 |
杨玲, 李连弟, 陈育德, 等. 中国2000年及2005年恶性肿瘤发病死亡的估计与预测. 中国卫生统计, 2005, 22(4): 218-231.
|
| 5 |
De GA, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 2000, 18(16): 2938-2947.
|
| 6 |
O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst, 2004, 96(19): 1420-1425.
|
| 7 |
Ochenduszko SL, Krzemieniecki K. Targeted therapy in advanced colorectal cancer: more data, more questions. Anticancer Drugs, 2010, 21(8): 737-748.
|
| 8 |
Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med, 2007, 357(20): 2040-2048.
|
| 9 |
Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol, 2007, 25(13): 1658-1664.
|
| 10 |
Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 2004, 22(7): 1201-1208.
|
| 11 |
Giusti RM, Shastri KA, Cohen MH, et al. FDA drug approval summary: Panitumumab (VectibixTM). Oncologist, 2007, 12: 577-583.
|
| 12 |
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351(4): 337-345.
|
| 13 |
Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol, 2005, 32(1): 52-60.
|
| 14 |
Patil DT, Fraser CR, Plesec TP. KRAS testing and its importance in colorectal cancer. Curr Oncol Rep, 2010, 12(3): 160-167.
|
| 15 |
Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res, 2006, 12(5): 1647-1653.
|
| 16 |
Barry EL, Baron JA, Grau MV, et al. Kras mutations in incident sporadic colorectal adenomas. Cancer, 2006, 106(5): 1036-1040.
|
| 17 |
Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev, 2000, 9(11): 1193-1197.
|
| 18 |
Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008, 359(17): 1757-1765.
|
| 19 |
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res, 2007, 67(6): 2643-2648.
|
| 20 |
Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer, 2007, 96(8): 1166-1169.
|
| 21 |
Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008, 26(3): 374-379.
|
| 22 |
Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26(10): 1626-1634.
|
| 23 |
Tejpar S, Peeters M, Humblet Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab(q1w): The EVEREST experience (preliminary data) (abstract). J Clin Oncol, 2008, 26(Suppl): 4001a.
|
| 24 |
Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26(14): 2311-2319.
|
| 25 |
Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 2009, 27(5): 663-671.
|
| 26 |
Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatmentfor metastatic colorectal cancer. N Engl J Med, 2009, 360(14): 1408-1417.
|
| 27 |
Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol, 2009, 27(12): 2091-2096.
|